Chronic hepatitis B and viral genotype: The clinical significance of determining HBV genotypes

Antiviral Therapy

Volumn 10, Issue 5, 2005, Pages 593-604

  Guettouche, Toumy ^a   Hnatyszyn, H James ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ASPARTIC ACID; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FUMARIC ACID; HEPATITIS B ANTIGEN; LAMIVUDINE; METHIONINE; PEGINTERFERON ALPHA2A; TENOFOVIR DISOPROXIL; THYMIDINE; THYMOSIN ALPHA1; TYROSINE;

B LYMPHOCYTE; BASE PAIRING; CHRONIC HEPATITIS; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; GENE MUTATION; GENOTYPE; GRAFT FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; INCIDENCE; INFECTION RISK; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEROCONVERSION; SIDE EFFECT; STOP CODON; VIRUS REPLICATION; VIRUS TRANSMISSION;

ALGORITHMS; ANTIVIRAL AGENTS; DISEASE PROGRESSION; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; TREATMENT OUTCOME; WORLD HEALTH;

EID: 24044446868     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Locarnini SA. Clinical relevance of viral dynamics and genotypes in hepatitis B virus. Journal of Gastroenterology & Hepatology 2002; 17(Suppl 3):S322-S328.
2. Lee CM, Chen CH, Lu SN, Tung HD, Chou WJ, Wang JH, Chen TM, Hung CH, Huang CC & Chen WJ. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scandanavian Journal of Gastroenterology 2003; 38:95-101
3. Hipgrave DB, Nguyen TV, Vu MH, Hoang TL, Do TD, Tran NT, Jolley D, Maynard JE & Biggs BA. Hepatitis B infection in rural Vietnam and the implications for a national program of infant immunization. American Journal of Tropical Medicine & Hygiene 2003; 69:288-294.
4. Souza KP, Luz JA, Teles SA, Carneiro MA, Oliveira LA, Gomes AS, Dias MA, Gomes SA, Yoshida CF & Martins RM. Hepatitis B and C in the hemodialysis unit of Tocantins, Brazil: serological and molecular profiles. Memorial Institute of Oswaldo Cruz 2003; 98:599-603.
5. Ding X, Gu H, Zhong ZH, Zilong X, Tran HT, Iwaki Y, Li TC, Sata T & Abe K. Molecular epidemiology of hepatitis viruses and genotypic distribution of hepatitis B and C viruses in Harbin, China. Japanese Journal of Infectious Diseases 2003; 56:19-22.
6. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 2004; 11:97-107.
7. Younossi ZM. Viral hepatitis guide for practicing physicians. Cleveland Clinic of Medicine. Cleveland Clinic Journal of Medicine 2000; 67(Suppl 1):S16-S45.
8. Hadziyannis SJ & Papatheodoridis GV. Emerging treatments in chronic hepatitis B. Expert Opinions in Emerging Drugs 2004; 9:207-221.
9. Pineiro YLFG, Mbayed VA and Campos RH. Evolutionary history of hepatitis B virus genotype F: an in-depth analysis of argentine isolates. Virus Genes 2003; 27:103-110.
10. Kann M. Structural and Molecular Virology. In Hepatitis B Virus, vol. 1 2002; pp. 9-22. Edited by Lai C-L & Locarnini S. London: International Medical Press.
11. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. Journal of Gastroenterology & Hepatology 2002; 17:643-650.
12. Jilbert AR, Burrell CJ, Triatni M & Kann M. Hepatitis B virus replication. In Hepatitis B Virus, 2002, pp. 43-53. Edited By Lai C-L & Locarnini S. London: International Medical Press.
13. Locarnini S, McMillan J & Bartholomeusz A. The hepatitis B virus and common mutants. Seminars in Liver Disease 2003; 23:5-20.
14. Younger HM, Bathgate AJ & Hayes PC. Review article: nucleoside analogues for the treatment of chronic hepatitis B. Alimentary Pharmacology Therapeutics 2004; 20:1211-1230.
15. Hollinger FB & Liang TJ. Hepatitis B virus. In Feild's Virolog, vol. 2 2001; 4th edn; pp. 2971-3036. Edited by Knipe DM & Hpwley PM. Philadelphia: Lippincott Williams and Wilkins.
16. Doo E & Liang TJ. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001; 120:1000-1008.
17. Seeger C & Mason WS. Hepatitis B virus biology. Microbiology & Molecular Biology Reviews 2000; 64:51-68.
18. Thakur V, Guptan RC, Kazim SN, Malhotra V & Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. Journal of Gastroenterology & Hepatology 2002; 17:165-170.
19. Orito E, Mizokami M, Ina Y, Moriyama EN, Kameshima N, Yamamoto M & Gojobori T. Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proceedings of the National Academy of Sciences, USA 1989; 86:7059-7062.
20. Okamoto H, Imai M, Kametani M, Nakamura T & Mayumi M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Japanese Journal of Experimental Medicine 1987; 57:231-236.
21. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF & Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. Journal of General Virology 2000; 81:67-74.
22. Kao JH & Chen DS. Global control of hepatitis B virus infection. Lancet Infectious Diseases 2002; 2:395-403.
23. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y & Mayumi M. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. Journal of General Virology 1988; 69(Pt 10):2575-2583.
24. Bartholomeusz A & Schaefer S. Hepatitis B virus genotypes: comparison of genotyping methods. Reviews in Medical Virology 2004; 14:3-16.
25. Clarke B & Bloor S. Molecular genotyping of hepatitis B virus. Journal of Clinical Virology 2002; 25(Suppl 3):S41-S45.
26. Cui C, Shi J, Hui L, Xi H, Zhuoma, Quni, Tsedan & Hu G. The dominant hepatitis B virus genotype identified in Tibet is a C/D hybrid. Journal of General Virology 2002; 83:2773-2777.
27. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, KaKumu S, Ishida T, Chutaputti A, Lai CL, Ueda R, Miyakawa Y & Mizokami M. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. Journal of Virology 2002; 76:5985-5992.
28. Suzuki S, Sugauchi F, Orito E, Kato H, Usuda S, Siransy L, Arita I, Sakamoto Y, Yoshihara N, El-Gohary A, Ueda R & Mizokami M. Distribution of hepatitis B virus (HBV) genotypes among HBV carriers in the Cote d'Ivoire: complete genome sequence and phylogenetic relatedness of HBV genotype E. Journal of Medical Virology 2003; 69:459-465.
29. Joh R, Hasegawa K, Ogawa M, Ishikawa K, Iizuka A, Naritomi T, Kanai N, Torii N, Hashimoto E & Hayashi N. Genotypic analysis of hepatitis B virus from patients with fulminant hepatitis: comparison with acute self-limited hepatitis. Hepatology Research 2003; 26:119-124.
30. Nakayoshi T, Maeshiro T, Nakasone H, Sakugawa H, Kinjo F, Orito E & Mizokami M. Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: a prospective study. Journal of Medical Virology 2003; 70:350-354.
31. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M & Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123:1848-1856.
32. Hussain M, Chu CJ, Sablon E & Lok AS. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. Journal of Clinical Microbiology 2003; 41:3699-3705.
33. Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K & Sablon E. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. Journal of Clinical Microbiology 2002; 40:3729-3734.
34. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, Kanda T, Fukai K, Kato M & Saisho H. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37:19-26.
35. Sugauchi F, Orito E, Kato H, Suzuki S, Kawakita S, Sakamoto Y, Fukushima K, Akiba T, Yoshihara N, Ueda R & Mizokami M. Genotype, serotype, and phylogenetic characterization of the complete genome sequence of hepatitis B virus isolates from Malawian chronic carriers of the virus. Journal of Medical Virology 2003; 69:33-40.
36. Sugauchi F, Chutaputti A, Orito E, Kato H, Suzuki S, Ueda R & Mizokami M. Hepatitis B virus genotypes and clinical manifestation among hepatitis B carriers in Thailand. Journal of Gastroenterology & Hepatology 2002; 17:671-676.
37. Arauz-Ruiz P, Norder H, Robertson BH & Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. Journal of General Virology 2002; 83:2059-2073.
38. Kao JH. Clinical relevance of hepatitis B viral genotypes: a case of deja vu? Journal of Gastroenterology & Hepatology 2002; 17:113-115.
39. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S & Magnius LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47:289-309.
40. Magnius LO & Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995; 38:24-34.
41. Westland C, Delaney Wt, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M & Xiong S. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003; 125:107-116.
42. Chu CJ & Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology 2002; 35:1274-1276.
43. Arankalle VA, Murhekar KM, Gandhe SS, Murhekar MV, Ramdasi AY, Padbidri VS & Sehgal SC. Hepatitis B virus: predominance of genotype D in primitive tribes of the Andaman and Nicobar islands, India (1989-1999). Journal of General Virology 2003; 84:1915-1920.
44. Gandhe SS, Chadha MS & Arankalle VA. Hepatitis B virus genotypes and serotypes in western India: lack of clinical significance. Journal of Medical Virology 2003; 69:324-330.
45. Rizzetto M. Hepatitis D: virology, clinical and epidemiological aspects. Acta Gastroenterology Belgium 2000; 63:221-224.
46. Kato H, Gish RG, Bzowej N, Newsom M, Sugauchi F, Tanaka Y, Kato T, Orito E, Usuda S, Ueda R, Miyakawa Y & Mizokami M. Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. Journal of Medical Virology 2004; 73:516-521.
47. Nguyen MH & Keeffe EB. Chronic hepatitis B and hepatitis C in Asian Americans. Reviews in Gastroenterological Disorders 2003; 3:125-134.
48. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown RS Jr, Luketic VA, Terrault N & Lok AS. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125:444-451.
49. Milich D & Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003; 38:1075-1086.
50. Gunther S, Fischer L, Pult I, Sterneck M & Will H. Naturally occurring variants of hepatitis B virus. Advances in Virus Research 1999; 52:25-137.
51. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown RS Jr, Luketic VA, Terrault N & Lok AS. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38:619-628.
52. Yuen MF, Sablon E, Wong DK, Yuan HJ, Wong BC, Chan AO & Lai CL. Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation. Clinical Infectious Diseases 2003; 37:593-597.
53. Rizzetto M, Volpes R & Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. Journal of Medical Virology 2000; 61:398-402.
54. Chin R & Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Reviews in Medical Virology 2003; 13:255-272.
55. Lagget M & Rizzetto M. Current pharmacotherapy for the treatment of chronic hepatitis B. Expert Opinions in Pharmacotherapy 2003; 4:1821-1827.
56. Colli A, Massironi S & Anreoletti M. Interferon therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2003; 38:779-780.
57. Yalcin K, Degertekin H, Yildiz F & Celik Y. Markers of disease activity in chronic hepatitis B virus infection. Clinical Investigative Medicine 2003; 26:27-34.
58. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Suzuki F, Akuta N, Hosaka T, Someya T, Matsuda M, Sato J, Takagi K, Miyakawa Y & Kumada H. Precore wild-type hepatitis B virus with G1896 in the resolution of persistent hepatitis B virus infection. Intervirology 2003; 46:157-163.
59. Lok AS, Akarca U & Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proceedings of the National Academy of Sciences, USA 1994; 91:4077-4081.
60. Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, Maisonnas M, Trepo C & Zoulim F. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. Journal of Hepatology 2000; 33:430-439.
61. Jardi R, Rodriguez F, Bud M, Costa X, Valdes A, Allende H, Schaper M, Galimany R, Esteban R & Guardia J. Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. Journal of Hepatology 2004; 40:507-514.
62. Bonino F & Brunetto MR. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. Journal of Hepatology 2003; 39:S160-S163.
63. Hadziyannis SJ & Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34:617-624.
64. Mayerat C, Mantegani A, Spertini F & Frei PC. Mutations in the basal core promoter and precore/core gene of hepatitis B virus in patients with chronic active but not acute hepatitis B. European Journal of Clinical Microbiology & Infectious Diseases 1999; 18:871-878.
65. Kawai K, Horiike N, Michitaka K & Onji M. The effects of hepatitis B virus core promoter mutations on hepatitis B core antigen distribution in hepatocytes as detected by laser-assisted microdissection. Journal of Hepatology 2003; 38:635-641.
66. Hunt CM, McGill JM, Allen MI & Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31:1037-1044.
67. Marrone A, Zampino R, Luongo G, Utili R, Karayiannis P & Ruggiero G. Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection. Intervirology 2003; 46:222-226.
68. Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, Niederau C & Haussinger D. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31:716-725.
69. Milich DR, Schodel F, Hughes JL, Jones JE & Peterson DL. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. Journal of Virology 1997; 71:2192-2201.
70. Kao JH, Chen PJ, Lai MY & Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124:327-334.
71. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A & Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847-851.
72. Pumpens P, Grens E & Nassal M. Molecular epidemiology and immunology of hepatitis B virus infection - an update. Intervirology 2002; 45:218-232.
73. Lok AS. Does interferon therapy for chronic hepatitis B reduce the risks of developing cirrhosis and hepatocellular carcinoma? Hepatology 1995; 22:1336-1338.
74. Bock CT, Tillmann HL, Maschek HJ, Manns MP & Trautwein C. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology 1997; 113:1976-1982.
75. Le Seyec J, Chouteau P, Cannie I, Guguen-Guillouzo C & Gripon P. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. Journal of Virology 1999; 73:2052-2057.
76. Sugauchi F, Ohno T, Orito E, Sakugawa H, Ichida T, Komatsu M, Kuramitsu T, Ueda R, Miyakawa Y & Mizokami M. Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. Journal of Medical Virology 2003; 70:537-544.
77. Ding X, Mizokami M, Ge X, Orito E, Iino S, Ueda R & Nakanishi M. Different hepatitis B virus genotype distributions among asymptomatic carriers and patients with liver diseases in Nanning, southern China. Hepatology Research 2002; 22:37-44.
78. Yuen MF, Sablon E, Yuan HJ, Wong DK, Hui CK, Wong BC, Chan AO & Lai CL. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003; 37:562-567.
79. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Suzuki F, Akuta N, Someya T, Matsuda M, Sato J & Kumada H. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. Journal of Gastroenterology 2002; 37:35-39.
80. Mayerat C, Mantegani A & Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? Journal of Viral Hepatitis 1999; 6:299-304.
81. Chu CJ, Hussain M & Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122:1756-1762.
82. Kao JH, Chen PJ, Lai MY & Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118:554-559.
83. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S & Mizokami M. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34:590-594.
84. Fujie H, Moriya K, Shintani Y, Yotsuyanagi H, Iino S & Koike K. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Gastroenterology 2001; 120:1564-1565.
85. Wai CT, Chu CJ, Hussain M & Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36:1425-1430.
86. Kao JH, Wu NH, Chen PJ, Lai MY & Chen DS. Hepatitis B genotypes and the response to interferon therapy. Journal of Hepatology 2000; 33:998-1002.
87. Furusyo N, Nakashima H, Kashiwagi K, Kubo N, Hayashida K, Usuda S, Mishiro S, Kashiwagi S & Hayashi J. Clinical outcomes of hepatitis B virus (HBV) genotypes B and C in Japanese patients with chronic HBV infection. American Journal of Tropical Medicine & Hygiene 2002; 67:151-157.
88. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saiton S, Suzuki F, Akuta N, Someya T, Matsuda M, Sato J, Takagi K, Miyakawa Y & Kumada H. Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. Journal of Medical Virology 2002; 68:522-528.
89. Liu X & Schinazi RF. Hepatitis B virus resistance to lamivudine and its clinical implications. Antiviral Chemistry & Chemotherapy 2002; 13:143-155.
90. Kao JH, Liu CJ & Chen DS. Hepatitis B viral genotypes and lamivudine resistance. Journal of Hepatology 2002; 36:303-304.
91. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL & Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. New England Journal of Medicine 1998; 339:61-68.
92. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M & Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. New England Journal of Medicine 1999; 341:1256-1263.
93. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, Someya T, Saitoh S, Arase Y, Ikeda K & Kumada H. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. Journal of Hepatology 2003; 38:315-321.
94. Ayres A, Bartholomeusz A, Lau G, Lam KC, Lee JY & Locarnini S. Lamivudine and famciclovir resistant hepatitis B virus associated with fatal hepatic failure. Journal of Clinical Virology 2003; 27:111-116.
95. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V & Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36:219-226.
96. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Matsuda M, Satoh J, Takagi K & Kumada H. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003; 46:182-189.
97. Papatheodoridis GV, Dimou E & Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. American Journal of Gastroenterology 2002; 97:1618-1628.
98. Leung NW. Management of viral hepatitis C. Journal of Gastroenterology & Hepatology 2002; 17(Suppl):S146-S154.
99. Delaney WE 4th, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD & Xiong S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. Journal of Virology 2003; 77:11833-11841.
100. Zollner B, Petersen J, Schroter M, Laufs R, Schoder V & Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001; 357:934-935.
101. Buti M, Cotrina M, Valdes A, Jardi R, Rodriguez-Frias F & Esteban R. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? Journal of Hepatology 2002; 36:445-446.
102. Qaqish RB, Mattes KA & Ritchie DJ. Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clinical Therapeutics 2003; 25:3084-3099.
103. Dando T & Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003; 63:2215-2234.
104. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df D, Sullivan M, Kleber K, Ebrahimi R, Xiong S & Brosgart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101.
105. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A & Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297.
106. Yadav V & Chu CK. Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants: a molecular dynamics study. Bioorganic & Medicinal Chemistry Letters 2004; 14:4313-4317.
107. Kuo A, Dienstag JL & Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clinical Gastroenterology & Hepatology 2004; 2:266-272.
108. Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B & Cheng AK. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and experienced patients coinfected with HIV-1 and hepatitis B virus. Journal of Infectious Diseases 2004; 189:1185-1192.
109. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T & Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antiviral Therapy 2004; 9:353-363.
110. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H & Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clincal Gastroenterology & Hepatology 2004; 2:87-106.